These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 9331797)
21. The human antibody response to streptococcal C5a peptidase. O'Connor SP; Darip D; Fraley K; Nelson CM; Kaplan EL; Cleary PP J Infect Dis; 1991 Jan; 163(1):109-16. PubMed ID: 1984457 [TBL] [Abstract][Full Text] [Related]
22. Evaluation of novel Streptococcus pyogenes vaccine candidates incorporating multiple conserved sequences from the C-repeat region of the M-protein. Bauer MJ; Georgousakis MM; Vu T; Henningham A; Hofmann A; Rettel M; Hafner LM; Sriprakash KS; McMillan DJ Vaccine; 2012 Mar; 30(12):2197-205. PubMed ID: 22265945 [TBL] [Abstract][Full Text] [Related]
23. HLA class II transgenic mice develop a safe and long lasting immune response against StreptInCor, an anti-group A streptococcus vaccine candidate. Guerino MT; Postol E; Demarchi LM; Martins CO; Mundel LR; Kalil J; Guilherme L Vaccine; 2011 Oct; 29(46):8250-6. PubMed ID: 21907752 [TBL] [Abstract][Full Text] [Related]
24. Pathogenesis of group A streptococci in mice and efficacy of locally administered streptococcal vaccines. Bronze MS; McKinsey DS; Beachey EH; Dale JB Trans Assoc Am Physicians; 1988; 101():88-92. PubMed ID: 3077732 [No Abstract] [Full Text] [Related]
25. Sequence and type-specific immunogenicity of the amino-terminal region of type 1 streptococcal M protein. Kraus W; Haanes-Fritz E; Cleary PP; Seyer JM; Dale JB; Beachey EH J Immunol; 1987 Nov; 139(9):3084-90. PubMed ID: 2444650 [TBL] [Abstract][Full Text] [Related]
26. [Molecular structure and immunochemistry of streptococcal M-protein]. Ookuni H Tanpakushitsu Kakusan Koso; 1990 Nov; 35(15):2839-51. PubMed ID: 1701908 [No Abstract] [Full Text] [Related]
27. Association between elevated serum antibody levels to streptococcal M12 protein and susceptibility to dermatomyositis. Ichimiya M; Yasui H; Hirota Y; Ohmura A; Muto M Arch Dermatol Res; 1998 Apr; 290(4):229-30. PubMed ID: 9617445 [No Abstract] [Full Text] [Related]
28. Serologic evidence for a class I group A streptococcal infection among rheumatic fever patients. Bessen DE; Veasy LG; Hill HR; Augustine NH; Fischetti VA J Infect Dis; 1995 Dec; 172(6):1608-11. PubMed ID: 7594728 [TBL] [Abstract][Full Text] [Related]
29. FbaA- and M protein-based multi-epitope vaccine elicits strong protective immune responses against group A streptococcus in mouse model. Ma C; Liu Z; Li W; Qian X; Zhang S; Gao X; Jiang S; Wei L Microbes Infect; 2014 May; 16(5):409-18. PubMed ID: 24704476 [TBL] [Abstract][Full Text] [Related]
30. Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes. Mannam P; Jones KF; Geller BL Infect Immun; 2004 Jun; 72(6):3444-50. PubMed ID: 15155651 [TBL] [Abstract][Full Text] [Related]
31. Bactericidal activity of M protein conserved region antibodies against group A streptococcal isolates from the Northern Thai population. Yoonim N; Olive C; Pruksachatkunakorn C; Pruksakorn S BMC Microbiol; 2006 Aug; 6():71. PubMed ID: 16895610 [TBL] [Abstract][Full Text] [Related]
32. Vimentin-cross-reactive epitope of type 12 streptococcal M protein. Kraus W; Seyer JM; Beachey EH Infect Immun; 1989 Aug; 57(8):2457-61. PubMed ID: 2473037 [TBL] [Abstract][Full Text] [Related]
33. A highly conserved region present in transcripts encoding heterologous M proteins of group A streptococci. Hollingshead SK; Fischetti VA; Scott JR Infect Immun; 1987 Dec; 55(12):3237-9. PubMed ID: 2445686 [TBL] [Abstract][Full Text] [Related]
34. Elevated IgG titer against the C region of streptococcal M protein and its immunodeterminants in patients with poststreptococcal acute glomerulonephritis. Mori K; Ito Y; Kamikawaji N; Sasazuki T J Pediatr; 1997 Aug; 131(2):293-9. PubMed ID: 9290619 [TBL] [Abstract][Full Text] [Related]
35. Mapping T-cell epitopes in group A streptococcal type 5 M protein. Robinson JH; Atherton MC; Goodacre JA; Pinkney M; Weightman H; Kehoe MA Infect Immun; 1991 Dec; 59(12):4324-31. PubMed ID: 1718873 [TBL] [Abstract][Full Text] [Related]
36. Human antibodies to the conserved region of the M protein: opsonization of heterologous strains of group A streptococci. Brandt ER; Hayman WA; Currie B; Pruksakorn S; Good MF Vaccine; 1997 Nov; 15(16):1805-12. PubMed ID: 9364687 [TBL] [Abstract][Full Text] [Related]
37. Induction of a mucosal immune response to the streptococcal M protein by intramuscular administration of a PADRE-ASREAK peptide. Pamonsinlapatham P; Decroix N; Mihaila-Amrouche L; Bouvet A; Bouvet JP Scand J Immunol; 2004 May; 59(5):504-10. PubMed ID: 15140061 [TBL] [Abstract][Full Text] [Related]
38. Mapping the minimal murine T cell and B cell epitopes within a peptide vaccine candidate from the conserved region of the M protein of group A streptococcus. Hayman WA; Brandt ER; Relf WA; Cooper J; Saul A; Good MF Int Immunol; 1997 Nov; 9(11):1723-33. PubMed ID: 9418133 [TBL] [Abstract][Full Text] [Related]
39. Epitopes of group A streptococcal M protein that evoke cross-protective local immune responses. Bronze MS; Courtney HS; Dale JB J Immunol; 1992 Feb; 148(3):888-93. PubMed ID: 1370521 [TBL] [Abstract][Full Text] [Related]
40. A lipid core peptide construct containing a conserved region determinant of the group A streptococcal M protein elicits heterologous opsonic antibodies. Olive C; Batzloff MR; Horváth A; Wong A; Clair T; Yarwood P; Toth I; Good MF Infect Immun; 2002 May; 70(5):2734-8. PubMed ID: 11953422 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]